过敏性哮喘合并慢性鼻窦炎伴鼻息肉应用抗IgE单抗长期治疗疗效分析

Long-term efficacy analysis of anti-IgE monoclonal antibody in patients with allergic asthma with chronic sinusitis with nasal polyps

目的观察抗IgE单克隆抗体(奥马珠单抗)治疗过敏性哮喘合并慢性鼻窦炎伴鼻息肉(CRSwNP)的长期治疗疗效。方法回顾性分析2020年9月至2023年12月期间经奥马珠单抗治疗满48周的4例过敏性哮喘合并CRSwNP患者的临床资料,在基线以及用药第4、12、24、48周回访时,对患者鼻部症状视觉模拟量表(VAS)评分、鼻腔鼻窦结局测试22(SNOT-22)评分及过敏性哮喘控制测试(ACT)评分进行数据收集。观察治疗后患者VAS、SNOT-22、ACT评分较基线的动态变化,对过敏性哮喘合并CRSwNP应用奥马珠单抗长期治疗疗效进行初步观察。结果经48周奥马珠单抗长期治疗后,4例患者鼻部症状有所改善,过敏性哮喘症状得到有效控制,生活质量有所提高,未发现任何严重不良反应的发生。结论本次临床观察初步显示,奥马珠单抗长期治疗过敏性哮喘合并CRSwNP具有一定疗效,但其疗效和安全性仍需证实。

Objective To observe the long-term efficacy of anti-IgE monoclonal antibody(omalizumab)in the treatment of allergic asthma combined with chronic sinusitis with nasal polyps(CRSwNP).Methods Clinical data of 4 patients with allergic asthma with CRSwNP between September 2020 and December 2023 were collected on visual analogue scale(VAS),sino-nasal outcome test-22(SNOT-22)scores and athma control test(ACT)scores baseline and at medication weeks 4,12,24 and 48.Observe the dynamic changes from baseline in VAS,SNOT-22 and ACT scores,and initially observe the long-term efficacy of omalizumab in allergic asthma with CRSwNP.Results After 48 weeks of omadizumab treatment,four patients showed improvement in nasal symptoms,effective control of allergic asthma symptoms,and improved quality of life.No serious adverse effects were observed during the treatment period.Conclusions This clinical observation preliminarily shows the long-term effectiveness of omalizumab in the treatment of allergic asthma combined with CRSwNP,but its efficacy and safety still need to be further confirmed by high-quality multicenter study with large clinical samples.